Literature DB >> 7143241

Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia.

K Hashimoto, H Satoh, T Shibuya, S Imai.   

Abstract

Seven drugs were tested for their antiarrhythmic effects on ventricular arrhythmias 24 and 48 hr after two-stage coronary ligation in conscious beagles. Venous blood samples were drawn for plasma drug assays. Minimum effective plasma concentrations of drugs were calculated from derived concentration-time curves. Effective drugs and their minimum effective concentrations for the suppression of arrhythmias 24 and 48 hr after coronary ligation were: disopyramide, 4.2 and 2.3 micrograms/ml; procainamide, 26.4 and 27.0 micrograms/ml; phenytoin, 8.4 and 6.4 micrograms/ml; and a new beta-blocker, N-696, 7.6 and 8.7 micrograms/ml. The concentrations of disopyramide and phenytoin were almost the same as those reported for human antiarrhythmic concentrations, but those of procainamide were higher than those reported for man. Lidocaine, verapamil and a new beta-blocker, OPC-1427, were ineffective. Membrane-stabilizing effects seem to be important in suppressing the canine two-stage coronary ligation arrhythmia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7143241

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Effects of HNS-32, a novel antiarrhythmic drug, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats.

Authors:  M Saitoh; N N Aye; S Komori; T Nakazawa; K Hashimoto
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

2.  Effects of bepridil and lidocaine on the intraventricular conduction in acutely ischaemic and infarcted canine myocardium.

Authors:  H Hashimoto; N Satoh; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

3.  Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.

Authors:  K Hashimoto; H Mitsuhashi
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

4.  Effects of a cardioselective M2 receptor antagonist, AF-DX 116, on ventricular arrhythmias in dogs.

Authors:  H Naito; Y Furukawa; K Hashimoto
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?

Authors:  K Hashimoto; A Haruno; T Matsuzaki; A Sugiyama; K Akiyama
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

6.  Comparison of the electrophysiological effects of Org 7797, disopyramide, mexiletine and propafenone in anaesthetized dogs with myocardial infarcts.

Authors:  J K Campbell; R J Marshall; E Winslow
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

7.  Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat.

Authors:  M J Curtis; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

8.  Anti-arrhythmic effects of (-)-carnitine chloride and its acetyl analogue on canine late ventricular arrhythmia induced by ligation of the coronary artery as related to improvement of mitochondrial function.

Authors:  S Imai; K Matsui; M Nakazawa; N Takatsuka; K Takeda; H Tamatsu
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

9.  Effects of a new class I antiarrhythmic drug bidisomide on canine ventricular arrhythmia models.

Authors:  W Zhenjiu; T Awaji; A Hirasawa; S Motomura; K Hashimoto
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

10.  Antiarrhythmic and electrophysiological effects of SD-3212, a novel Na+ and Ca++ channel blocker, in anaesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3211) and bepridil.

Authors:  S Nagashima; T Uematsu; S Araki; T Matsuzaki; M Fukuchi; H Hashimoto; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.